Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia

S. MacCallum; M. Groves; D. Brass; J. Cunningham; M. Sales; K. Gelly; S. Tauro

doi:10.1136/jcp.2008.061143

Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia

S. MacCallum
, M. Groves
, D. Brass
, J. Cunningham
, M. Sales
, K. Gelly
, S. Tauro

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Autoimmune haemolysis or thrombocytopenia can complicate purine nucleoside monotherapy for chronic lymphocytic leukaemia (CLL), but Evans syndrome is rare. This is a report of the occurrence of pancytopenia secondary to a unique combination of red cell aplasia with autoimmune thrombocytopenia and neutropenia in a patient with CLL following treatment with fludarabine and cyclophosphamide. This case is unusual for the simultaneous targeting of three haemopoietic lineages by immune dysfunction following fludarabine and cyclophosphamide, which is a treatment regimen believed to reduce autoimmune haematological toxicity in CLL.

Original language	English
Pages (from-to)	468-470
Number of pages	3
Journal	Journal of Clinical Pathology
Volume	62
Issue number	5
DOIs	https://doi.org/10.1136/jcp.2008.061143
Publication status	Published - 2009

Keywords

RED-CELL APLASIA
FLUDARABINE
CYCLOPHOSPHAMIDE
CLL
RITUXIMAB

Access to Document

10.1136/jcp.2008.061143

Cite this

@article{e6240ddceb98491ab8219086235e2b90,

title = "Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia",

abstract = "Autoimmune haemolysis or thrombocytopenia can complicate purine nucleoside monotherapy for chronic lymphocytic leukaemia (CLL), but Evans syndrome is rare. This is a report of the occurrence of pancytopenia secondary to a unique combination of red cell aplasia with autoimmune thrombocytopenia and neutropenia in a patient with CLL following treatment with fludarabine and cyclophosphamide. This case is unusual for the simultaneous targeting of three haemopoietic lineages by immune dysfunction following fludarabine and cyclophosphamide, which is a treatment regimen believed to reduce autoimmune haematological toxicity in CLL.",

keywords = "RED-CELL APLASIA, FLUDARABINE, CYCLOPHOSPHAMIDE, CLL, RITUXIMAB",

author = "S. MacCallum and M. Groves and D. Brass and J. Cunningham and M. Sales and K. Gelly and S. Tauro",

year = "2009",

doi = "10.1136/jcp.2008.061143",

language = "English",

volume = "62",

pages = "468--470",

journal = "Journal of Clinical Pathology",

issn = "0021-9746",

publisher = "BMJ Publishing Group",

number = "5",

}

TY - JOUR

T1 - Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia

AU - MacCallum, S.

AU - Groves, M.

AU - Brass, D.

AU - Cunningham, J.

AU - Sales, M.

AU - Gelly, K.

AU - Tauro, S.

PY - 2009

Y1 - 2009

N2 - Autoimmune haemolysis or thrombocytopenia can complicate purine nucleoside monotherapy for chronic lymphocytic leukaemia (CLL), but Evans syndrome is rare. This is a report of the occurrence of pancytopenia secondary to a unique combination of red cell aplasia with autoimmune thrombocytopenia and neutropenia in a patient with CLL following treatment with fludarabine and cyclophosphamide. This case is unusual for the simultaneous targeting of three haemopoietic lineages by immune dysfunction following fludarabine and cyclophosphamide, which is a treatment regimen believed to reduce autoimmune haematological toxicity in CLL.

AB - Autoimmune haemolysis or thrombocytopenia can complicate purine nucleoside monotherapy for chronic lymphocytic leukaemia (CLL), but Evans syndrome is rare. This is a report of the occurrence of pancytopenia secondary to a unique combination of red cell aplasia with autoimmune thrombocytopenia and neutropenia in a patient with CLL following treatment with fludarabine and cyclophosphamide. This case is unusual for the simultaneous targeting of three haemopoietic lineages by immune dysfunction following fludarabine and cyclophosphamide, which is a treatment regimen believed to reduce autoimmune haematological toxicity in CLL.

KW - RED-CELL APLASIA

KW - FLUDARABINE

KW - CYCLOPHOSPHAMIDE

KW - CLL

KW - RITUXIMAB

U2 - 10.1136/jcp.2008.061143

DO - 10.1136/jcp.2008.061143

M3 - Article

C2 - 19398596

SN - 0021-9746

VL - 62

SP - 468

EP - 470

JO - Journal of Clinical Pathology

JF - Journal of Clinical Pathology

IS - 5

ER -

Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia

Abstract

Keywords

Access to Document

Fingerprint

Cite this